Clinical Trial Update: PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating predictive factors and treatment changes among af Libercept regimens for central serous chorioretinopathy and age-related macula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Central Serous Chorioretinopathy

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Central Serous Chorioretinopathy, Age Related Macular Degeneration | Phase 4 | Status: UNKNOWN